302 related articles for article (PubMed ID: 15643512)
1. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
Lorusso V; Crucitta E; Silvestris N; Rosati G; Manzione L; De Lena M; Palmeri S; Gebbia V; Mancarella S; Sobrero A; Pezzella G; Comella P; Mangiameli A; Muci D;
Oncol Rep; 2005 Feb; 13(2):283-7. PubMed ID: 15643512
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
[TBL] [Abstract][Full Text] [Related]
3. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
Ecke TH; Gerullis H; Bartel P; Koch S; Ruttloff J
Minerva Urol Nefrol; 2009 Mar; 61(1):1-8. PubMed ID: 19417721
[TBL] [Abstract][Full Text] [Related]
4. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A
Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Dogliotti L; Cartenì G; Siena S; Bertetto O; Martoni A; Bono A; Amadori D; Onat H; Marini L
Eur Urol; 2007 Jul; 52(1):134-41. PubMed ID: 17207911
[TBL] [Abstract][Full Text] [Related]
6. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
[TBL] [Abstract][Full Text] [Related]
7. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
Li J; Juliar B; Yiannoutsos C; Ansari R; Fox E; Fisch MJ; Einhorn LH; Sweeney CJ
J Clin Oncol; 2005 Feb; 23(6):1185-91. PubMed ID: 15718315
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium.
Ecke TD; Gerullis H; Bartel P; Koch S; Ruttloff J
Minerva Urol Nefrol; 2009 Sep; 61(3):249-56. PubMed ID: 19773726
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium.
Xu N; Zhang XC; Xiong JP; Fang WJ; Yu LF; Qian J; Zhang L
BMC Cancer; 2007 Jun; 7():98. PubMed ID: 17559681
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
Artz A; Stadler WM; Vogelzang NJ; Zimmerman T; Ryan C
Am J Clin Oncol; 2005 Apr; 28(2):109-13. PubMed ID: 15803001
[TBL] [Abstract][Full Text] [Related]
15. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
16. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
Meluch AA; Greco FA; Burris HA; O'Rourke T; Ortega G; Steis RG; Morrissey LH; Johnson V; Hainsworth JD
J Clin Oncol; 2001 Jun; 19(12):3018-24. PubMed ID: 11408496
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
Hutson TE; Vukelja S; Atienza D; Awasthi S; Delaune R; Deutsch M; Dien PY; Gregory TF; Kolodziej MJ; Muscato JJ; Raju RN; Ruxer RL; Mull S; Ilegbodu D; Hood K; Nicol S; Berry W
Invest New Drugs; 2008 Apr; 26(2):151-8. PubMed ID: 18236006
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Halim A; Abotouk N
Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
